The World Orphan Drug Congress 2026 brings together leaders in strategy, advocacy, and partnering from the orphan drug industry. It serves as a forum for industry professionals, regulators, patients, and other stakeholders to discuss the latest trends, innovations, and challenges in the orphan drug field.
Artificial intelligence is rapidly becoming an integral part of the rare disease ecosystem, supporting scientific discovery, therapeutic development and strategic decision-making. …
Moving beyond isolated advocacy to accelerate diagnosis, this workshop will holistically explore how early diagnosis fits within the rare disease ecosystem from development of diag…
- The need for a separate approval pathway for Orphan Drugs - How will new Reimbursement models help Pharmaceutical companies navigate Orphan Drug development?
A Rare Networking Opportunity brings together rare disease patient advocates and professionals working towards rare disease therapies - not to pitch or present, but to genuinely co…
- What’s in the pipeline and what rare diseases have been targeted? - How have global launch strategies been impacted by MFN? - Emerging platforms (gene, cell, RNA etc) and novel t…
Europe’s first JCAs have now been published, providing initial opportunity to examine how rare disease patient and caregiver perspectives are incorporated into assessment and wheth…
What does it mean when 87 companies show up, and 2 bet on three roles at once?
The numbers below are derived from the speakers, sponsors, and exhibitors on this page, cross-referenced into one ledger. They are the only thing here that 10times.com cannot tell you.
The Triple-Threat
48% of the speakers carry senior titles: C-suite, Founder, VP, or Director-level.
Of 61 on the bill · classified by free-text title
These companies sponsored two or more peer events recently, but aren't on this program. For an organizer, that's a list of warm prospects.
Related events
Same brand, other regions